Cycle-to-cycle Variability of Progesterone in the Endometrium in Patients Undergoing an Euploid Blastocyst Transfer in a Hormone Replacement Therapy (HRT) Cycle (PROMICOFET)

This study looks at progesterone, a hormone that prepares the womb lining (endometrium) for pregnancy, in women having a frozen embryo transfer after IVF. Before an embryo is transferred, women take estrogen and progesterone medication to prepare the endometrium. Doctors currently check progesterone levels in the blood, but blood levels do not always match what is happening in the endometrium itself, and it is not yet known whether progesterone levels in the womb tissue stay the same from one treatment cycle to the next.
The study also looks at whether hormone levels relate to how the uterus contracts, to the bacteria naturally present in the vagina, cervix, uterus and gut, and to tiny particles released by cells (called extracellular vesicles) that may help the embryo and the womb "communicate" during implantation.
Participants are women who are already waiting for genetic test results on their embryos, a wait that typically lasts around 8 weeks. During this time, they go through two practice ("mock") treatment cycles using the same hormone medications as a real embryo transfer, but without an actual embryo. During these cycles, researchers collect blood and urine samples, a small tissue sample from the womb lining, swabs from the vagina, cervix and rectum, and a short ultrasound recording of womb movement. Afterwards, participants proceed with their real embryo transfer cycle, with similar (though fewer) measurements taken, and are followed to see whether they become pregnant.
The findings from this study may help doctors better understand how to personalize hormone treatment for future frozen embryo transfers, with the aim of improving pregnancy outcomes.

开始日期2026-10-01

申办/合作机构

Ghent University Hospital

[+1]

100 项与戊酸雌二醇相关的临床结果

登录后查看更多信息

100 项与戊酸雌二醇相关的转化医学

登录后查看更多信息

100 项与戊酸雌二醇相关的专利（医药）

登录后查看更多信息

1,665

项与戊酸雌二醇相关的文献（医药）

2026-11-01·TISSUE & CELL

The effect of platelet-rich plasma extracellular vesicles (PRP-EVs) on the expression of BECN1, CYP19a1, and BMP6 as critical genes related to autophagy and steroidogenesis in ovarian granulosa cells of polycystic ovarian syndrome (PCOS) mouse model

Article

作者: Amini, Elaheh ; Mirabolghasemi, Seyedeh Ghadireh ; Namin, Sanam Poorhashem ; Azarnia, Mahnaz

BACKGROUND:

Polycystic ovarian syndrome (PCOS) is the most common endocrine condition in which aberrant expression of androgens leads to disrupted steroidogenesis, increased apoptosis, as well as autophagy in granulosa cells (GCs) and impaired ovulation. Here, we evaluated the therapeutic capacity of extracellular vesicles derived from platelet-rich plasma (PRP-EVs) on the expression of genes related to autophagy and steroidogenesis in ovarian GCs of PCOS mouse model.

METHODS:

In this experimental study, 40 female NMRI mice were classified into four groups, including control (untreated) and experimental groups 2, 3, and 4 (n = 8). The experimental group of 2 was considered as PCOS mice. PCOS was induced using a single subcutaneous injection of estradiol valerate (4 mg/kg). In the experimental groups of 3 and 4, (60 days after PCOS induction) PRP-EVs were injected intraperitoneally at doses of 25 and 50 µg/kg body weight for two consecutive weeks. For this purpose, PRP-EVs were isolated from eight NMRI mice and characterized with DLS, as well as assessment the CD63 EVs marker using flow cytometry. The effect of PRP-EVs on the PCOS ovaries was evaluated by analyzing serum hormone levels and histological analysis. Finally, assessment of the steroidogenic and autophagic gene expression was performed in isolated ovarian GCs using quantitative real-time polymerase chain reaction (qRT-PCR).

RESULTS:

According to the hormonal analysis, PCOS mice had a decreased FSH/LH ratio compared to the control group. Histological data also showed more cystic follicles (CF) and more occasional healthy follicles in PCOS mice. Furthermore, in PCOS-induced mice, attenuation of CYP19a1, as well as an increment in BECN1 and BMP6, was observed in the transcriptional levels of isolated GCs. In contrast, the FSH/LH ratio and ovarian structures were revitalized by PRP-EVs treatment (50 µg/kg body weight). In addition, gene expression analysis exhibited CYP19a1 up-regulation, as well as BECN1 and BMP6 down-regulation in ovarian GCs under exposure to an optimum dose of PRP-EVs.

CONCLUSION:

Overall, our study suggests that PRP-EVs can be suggested as a promising biopharmaceutical source for PCOS conditions as a novel therapeutic option. Despite this advance, purifying EVs, quantifying EVs by particle size, providing safety, and determining fertility outcomes hinder the clinical application of PRP-EVs.

2026-09-01·COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING

Mechanistic Insights into the Therapeutic Effects of Zishen Yutai Pill on Premature Ovarian Insufficiency via the RIPK1/RIPK3/MLKL Necroptosis Pathway

Article

作者: Chen, Yingyin ; Zhao, Ying ; Feng, Yihui

Introduction/Objective::

Zishen Yutai Pill (ZYP) has shown clinical efficacy in the treatment of Premature Ovarian Insufficiency (POI). However, its underlying mechanisms remain unclear. This study aimed to investigate the therapeutic effects and underlying mechanism of ZYP in cyclophosphamide (CTX)-induced POI in rats.

Methods::

A total of 119 female rats were divided into two groups: blank controls (n=17) and POI rat model (n=102). POI rats were randomly assigned (n = 17 per group) to six groups: POI model controls or five treatments, including low-dose ZYP, high-dose ZYP, caspase inhibitor, RIPK1 inhibitor, or estradiol valerate (positive control). Sex hormone levels of folliclestimulating hormone (FSH), estradiol (E2), and Anti-Müllerian Hormone (AMH) were assessed by enzyme-linked immunosorbent assay. Ovarian morphology was assessed by Hematoxylin and Eosin (H&E) staining and Transmission Electron Microscopy (TEM). The expression of apoptosis- and necroptosis-related proteins, including caspase-3, caspase-8, tumor necrosis factor-alpha (TNF-α), RIPK1, RIPK3, and MLKL, was assessed by immunohistochemistry, western blot (WB), and immunofluorescence (IF).

Results::

ZYP improved general condition and stabilized body weight in POI rats. It significantly decreased FSH while increasing E2 and AMH (p<0.001). High-dose ZYP increased primary (p<0.05) and antral follicles (p<0.001), and reduced atretic follicles (p<0.001). Ultrastructural damage was alleviated. ZYP downregulated apoptosis- and necroptosis-related proteins (caspase- 8, caspase-3, TNF-α, RIPK1, RIPK3, MLKL) (p<0.001), comparable to the RIPK1 inhibitor. WB and IF further showed that ZYP high dose group significantly downregulated RIPK3 and MLKL expression (p<0.001).

Discussion::

These findings provide mechanistic insight into the protective role of ZYP and support its potential as a therapeutic strategy for POI.

Conclusion::

ZYP ameliorates CTX-induced POI by regulating hormones, improving ovarian morphology, and inhibiting the RIPK1/RIPK3/MLKL pathway.

2026-08-08·International Journal of Fertility & Sterility

The Effectiveness of Pelvic Floor Physiotherapy on Endometrial Thickness during Embryo Transfer in Infertile Women: A Systematic Review and Meta-analysis.

Review

作者: Farasati, Mahsa ; Abdolalipour, Somayeh ; Mirghafourvand, Mojgan ; Mohammad-Alizadeh-Charandabi, Sakineh

Objective:

Embryo transfer is a complex process that often fails due to poor endometrial growth. Pelvic floor physiotherapy improves endometrial thickness by enhancing pelvic blood circulation and stimulating uterine muscle with varied frequency flows, consequently boosting embryo implantation and pregnancy success rates. The present study aimed to assess the effectiveness of pelvic floor physiotherapy on endometrial thickness during embryo transfer.

Materials and Methods:

We systematically reviewed databases with no time restriction (out of 574 retrieved records, 8 studies were meta-analysed). This study analyzed randomized controlled trials (RCTs) assessing pelvic floor physiotherapy effects on endometrial thickness in infertile women, compared to routine treatments such as estradiol valerate tablets with vaginal progesterone gel, and oral Progynova. Participants were infertile women undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer (IVF/ICSI-ET) or frozen ET (FET). Outcomes included endometrial thickness (primary outcome), arterial resistance index (RI), pulsatility index (PI), and pregnancy rate (secondary outcomes).

Results:

A total of 8 studies were meta-analyzed and we found that electrical physiotherapy combined with routine treatments, may increase the endometrial thickness versus controls [mean difference (MD)=0.93, 95% confidence interval (CI): 0.30 to 1.55; 7 trials, P=0.004; low-certainty evidence], but does not affect RI (MD=-0.03, 95% CI: -0.14 to 0.07; 4 trials, P=0.570; very low-certainty evidence) and PI (MD=-0.16, 95% CI: -0.41 to 0.09; 3 trials, P=0.210; very low-certainty evidence). However, physiotherapy with routine treatments may increase pregnancy rates with low-quality evidence (OR=2.72, 95% CI: 1.87 to 3.95; 6 trials, P<0.001; low-certainty evidence).

Conclusion:

Our study suggests that combining pelvic floor physiotherapy with standard infertility treatments may enhance endometrial thickness and boost fertility rates compared to standard treatments alone. Critically, this conclusion is based on low to very low-quality evidence, limiting confidence in the observed benefits. Furthermore, the effect of physiotherapy on uterine arterial resistance and pulsatility indices is currently undetermined due to insufficient data (Prospero ID: CRD42023442310).

106

项与戊酸雌二醇相关的新闻（医药）

2026-10-22

·信狐药迅

2款1类国产新药：联环联格列净、智翔金泰泰利奇拜单抗提交上市申请|新受理（10.12-10.21）

本周药品注册受理数据，分门别类呈现，一目了然。(10.12-10.21）新药上市申请药品名称企业注册分类受理号注射用伦康依隆妥单抗成都百利多特生物药业有限责任公司 2.2 CXSS2600166 多替拉韦拉米夫定替诺福韦片江苏艾迪药业集团股份有限公司 2.3 CXHS2600142 联格列净片江苏联环药业股份有限公司 1 CXHS2600141 联格列净片江苏联环药业股份有限公司 1 CXHS2600140 泰利奇拜单抗注射液(皮下注射) 重庆智翔金泰生物制药股份有限公司 1 CXSS2600163 贝泽昔替尼片杭州邦顺制药股份有限公司 2.4 CXHS2600139 贝泽昔替尼片杭州邦顺制药股份有限公司 2.4 CXHS2600138 盐酸吉卡昔替尼片苏州泽璟生物制药股份有限公司 2.4 CXHS2600137新药临床申请药品名称企业注册分类受理号甘草酸单铵乳膏南京易腾药物研究院有限公司 2.2 CXHL2601309 SHR-2614眼内注射液上海盛迪医药有限公司 1 CXSL2601154 SHR-2614眼内注射液上海盛迪医药有限公司 1 CXSL2601153 IBI363 信达生物制药(苏州)有限公司 1 CXSL2601152 IBI363 信达生物制药(苏州)有限公司 1 CXSL2601151 注射用SIM0500 上海先声再明医药生物科技有限公司 1 CXSL2601158 注射用SIM0500 上海先声再明医药生物科技有限公司 1 CXSL2601157 SHR-4610注射液上海盛迪医药有限公司 1 CXSL2601156 注射用CGB3002 迦进生物医药(上海)有限公司 1 CXSL2601155 HRS-7058胶囊山东盛迪医药有限公司 1 CXHL2601313 HRS-7058胶囊山东盛迪医药有限公司 1 CXHL2601312 HRS-7058片山东盛迪医药有限公司 1 CXHL2601311 HRS-7058片山东盛迪医药有限公司 1 CXHL2601310 注射用DB-1311 映恩生物制药(苏州)有限公司 1 CXSL2601160 SHR-3045注射液广东恒瑞医药有限公司 1 CXSL2601159 注射用AS006 中国科学院上海药物研究所 1 CXHL2601314 注射用泰它西普荣昌生物制药(烟台)股份有限公司 2.2 CXSL2601161 德瓦扑拜单抗注射液百奥泰生物制药股份有限公司 1 CXSL2601150 GenSci155注射液长春金赛药业有限责任公司 1 CXSL2601149 GenSci155注射液长春金赛药业有限责任公司 1 CXSL2601148 注射用BPI-585771 贝达药业股份有限公司 1 CXHL2601308 QLS1530片上海齐鲁制药研究中心有限公司 1 CXHL2601304 QLS1530片上海齐鲁制药研究中心有限公司 1 CXHL2601303 YY2403口崩片药云(西安)医药技术有限公司 2.2 CXHL2601302 HP-001胶囊上海超阳药业有限公司 1 CXHL2601301 HP-001胶囊上海超阳药业有限公司 1 CXHL2601300 HP-001胶囊上海超阳药业有限公司 1 CXHL2601299 注射用LY4170156 礼来苏州制药有限公司 1 CXSL2601139 SHR-5670注射液江苏恒瑞医药股份有限公司 1 CXSL2601142 HPN-01肠溶胶囊和博恒升(上海)医药有限公司 1 CXHL2601306 HPN-01肠溶胶囊和博恒升(上海)医药有限公司 1 CXHL2601305 PA-XP-102 中科帅天医药(深圳)有限公司 1 CXHL2601307 SHR-5670注射液江苏恒瑞医药股份有限公司 1 CXSL2601147 注射用TQB6411 上海正大天晴医药科技开发有限公司 1 CXSL2601146 重组抗NKG2A人源化单克隆抗体注射液上海怀越生物科技有限公司 1 CXSL2601145 B1962注射液天士力生物医药股份有限公司 1 CXSL2601144 B1962注射液天士力生物医药股份有限公司 1 CXSL2601143 注射用JNJ-98768111 强生(中国)投资有限公司 1 CXSL2601138 人脐带间充质干细胞注射液湖南光琇高新生命科技有限公司 1 CXSL2601135 SCTB41注射液神州细胞工程有限公司 1 CXSL2601137 SCTC21C注射液神州细胞工程有限公司 1 CXSL2601136 烟酰胺腺嘌呤二核苷酸片康诺生物制药股份有限公司 2.2;2.4 CXHL2601295 LX2423片上海力芯联创生物医药科技有限公司 2.1;2.3 CXHL2601294 VC005片江苏威凯尔医药科技股份有限公司 1 CXHL2601296 LW402片上海长森药业有限公司 1 CXHL2601298 LW402片上海长森药业有限公司 1 CXHL2601297 31价肺炎球菌多糖结合疫苗山东坤力生物制药有限责任公司 1.4 CXSL2601126 注射用BC602 宝船生物医药科技(上海)有限公司 1 CXSL2601125 RH125注射液武汉瑞佶生物科技有限公司 1 CXSL2601127 YH601软膏杭州禹泓医药科技有限公司 1 CXHL2601284 YH601软膏杭州禹泓医药科技有限公司 1 CXHL2601283 FY105注射液北京福元医药股份有限公司 1 CXHL2601287 TLL-041片杭州高光制药股份有限公司 1 CXHL2601286 TLL-041片杭州高光制药股份有限公司 1 CXHL2601285 AI-081注射液南京昂科免疫生物医药有限公司 1 CXSL2601130 AI-081注射液南京昂科免疫生物医药有限公司 1 CXSL2601129 LY-M001 注射液凌意(杭州)生物科技有限公司 1 CXSL2601128 IN10018片应世生物科技(深圳)有限公司 1 CXHL2601290 IN10018片应世生物科技(深圳)有限公司 1 CXHL2601289 注射用BGB-B2033 广州百济神州生物制药有限公司 1 CXSL2601131 BPI-572270胶囊杭州景曜生物科技有限责任公司 1 CXHL2601293 BPI-572270胶囊杭州景曜生物科技有限责任公司 1 CXHL2601292 BPI-572270胶囊杭州景曜生物科技有限责任公司 1 CXHL2601291 ART104注射液苏州昂拓生物医药有限公司 1 CXHL2601288 DS001注射用冻干粉针杭州达迈生物科技有限公司 1 CXSL2601134 HS-20169注射液上海翰森生物医药科技有限公司 1 CXSL2601133 注射用MCLA-129 贝达药业股份有限公司 1 CXSL2601132 LK101注射液 1 CXSL2601115 SIM0712胶囊江苏先声药业有限公司 1 CXHL2601277 注射用BAT7112 百奥泰生物制药股份有限公司 1 CXSL2601117 SSGJ-706注射液沈阳三生制药有限责任公司 1 CXSL2601116 SIM0712胶囊江苏先声药业有限公司 1 CXHL2601278 SPGL008注射液深圳赛保尔生物药业有限公司 1 CXSL2601118 富马酸泰吉利定注射液江苏恒瑞医药股份有限公司 2.4 CXHL2601280 富马酸泰吉利定注射液江苏恒瑞医药股份有限公司 2.4 CXHL2601279 注射用BG-T0050 广州百济神州生物制药有限公司 1 CXSL2601124 IBI324 信达生物制药(苏州)有限公司 1 CXSL2601123 注射用重组E型肉毒毒素河北封章生物科技有限公司 1 CXSL2601122 SYS6095注射液北京抗创联生物制药技术研究有限公司 1 CXSL2601121 SYS6095注射液北京抗创联生物制药技术研究有限公司 1 CXSL2601120 KYS202010A注射用冻干制剂江苏康缘药业股份有限公司 1 CXSL2601119 ACT001胶囊尚德药缘(天津)生物制药有限公司 1 CXHL2601282 SYH2078注射液石药集团中诺药业(石家庄)有限公司 1 CXHL2601281 CS23546片深圳微芯生物科技股份有限公司 1 CXHL2601266 SIBP-A21注射液上海生物制品研究所有限责任公司 1 CXSL2601108 WYY026B注射液北京红惠新医药科技有限公司 1 CXHL2601262 ARTS-023片安锐生物医药科技(广州)有限公司 1 CXHL2601264 ARTS-023片安锐生物医药科技(广州)有限公司 1 CXHL2601263 注射用TJ101 正大天晴药业集团股份有限公司 1 CXSL2601107 注射用DL001 成都登隆生物医药有限公司 1 CXHL2601269 CS23546片深圳微芯生物科技股份有限公司 1 CXHL2601268 CS23546片深圳微芯生物科技股份有限公司 1 CXHL2601267 CS23546片深圳微芯生物科技股份有限公司 1 CXHL2601265 Daraxonrasib片百济神州(上海)生物科技有限公司 2.4 CXHL2601273 Daraxonrasib片百济神州(上海)生物科技有限公司 2.4 CXHL2601272 Daraxonrasib片百济神州(上海)生物科技有限公司 2.4 CXHL2601271 Zoldonrasib片百济神州(上海)生物科技有限公司 1 CXHL2601270 AI-081注射液南京昂科免疫生物医药有限公司 1 CXSL2601114 AI-081注射液南京昂科免疫生物医药有限公司 1 CXSL2601113 IMC-003 宜明凯尔生物医药技术(上海)有限公司 1 CXSL2601112 SHR-6129注射液苏州盛迪亚生物医药有限公司 1 CXSL2601111 SI-B001双特异性抗体注射液成都百利多特生物药业有限责任公司 1 CXSL2601110 注射用BL-B01D1 成都百利多特生物药业有限责任公司 2.2 CXSL2601109 BGB-58067片百济神州(苏州)生物科技有限公司 1 CXHL2601276 BGB-58067片百济神州(苏州)生物科技有限公司 1 CXHL2601275 NME注射液北京藏卫信康医药研发有限公司 2.3 CXHL2601274 抗狂犬病病毒全人源组合抗体注射液辽宁成大生物股份有限公司 1 CXSL2601104 阿得贝利单抗注射液上海盛迪医药有限公司 2.2 CXSL2601099 SYS6072 石药集团巨石生物制药有限公司 1 CXSL2601098 9MW5211注射液迈威(上海)生物科技股份有限公司 1 CXSL2601097 注射用QLS5314 上海齐鲁制药研究中心有限公司 1 CXSL2601101 注射用HS-20122 上海翰森生物医药科技有限公司 1 CXSL2601100 HP570片海创药业股份有限公司 1 CXHL2601261 HP570片海创药业股份有限公司 1 CXHL2601260 HP570片海创药业股份有限公司 1 CXHL2601259 注射用泰它西普荣昌生物制药(烟台)股份有限公司 2.2 CXSL2601103 注射用LM-338 礼新医药科技(上海)有限公司 1 CXSL2601102 QH104A细胞注射液北京清辉联诺生物科技有限责任公司 1 CXSL2601105 注射用GB268 亿腾医药(珠海)有限公司 1 CXSL2601106仿制药申请药品名称企业注册分类受理号多种微量元素注射液(III) 华润双鹤药业股份有限公司 4 CYHS2602586 盐酸决奈达隆片南通慧聚制药有限公司 4 CYHS2602585 左乙拉西坦口服溶液武汉人福药业有限责任公司 4 CYHS2602577 乙酰半胱氨酸口服液葵花药业集团(冀州)有限公司 3 CYHS2602584 玻璃酸钠滴眼液山东海山药业有限公司 4 CYHS2602576 乙酰半胱氨酸口服液葵花药业集团(冀州)有限公司 3 CYHS2602583 环硅酸锆钠散宁波美诺华天康药业有限公司 4 CYHS2602582 环硅酸锆钠散宁波美诺华天康药业有限公司 4 CYHS2602581 达格列净片江西制药有限责任公司 4 CYHS2602580 达格列净片江西制药有限责任公司 4 CYHS2602579 酒石酸唑吡坦缓释片西安远大德天药业股份有限公司 3 CYHL2600119 酒石酸唑吡坦缓释片西安远大德天药业股份有限公司 3 CYHL2600118 巴瑞替尼片山东良福制药有限公司 4 CYHS2602588 富马酸卢帕他定片海南赛立克药业有限公司 4 CYHS2602587 拉西地平片杭州泓友医药科技有限公司 4 CYHS2602575 异甘草酸镁注射液北京远方通达医药技术有限公司 4 CYHS2602578 复方聚乙二醇(3350)电解质口服溶液湖北多瑞药业有限公司 3 CYHS2602564 夫西地酸乳膏武汉市小铂生物科技有限公司 4 CYHS2602563 盐酸苯海拉明片河南朗冠药品制剂研究院有限公司 3 CYHS2602562 磷酸芦可替尼片新天地药业股份有限公司 4 CYHS2602561 磷酸芦可替尼片新天地药业股份有限公司 4 CYHS2602560 磷酸芦可替尼片新天地药业股份有限公司 4 CYHS2602559 精氨酸布洛芬颗粒石家庄市华新药业有限责任公司 4 CYHS2602558 精氨酸布洛芬颗粒石家庄市华新药业有限责任公司 4 CYHS2602557 牛磺熊去氧胆酸胶囊湖北知化医药科技有限公司 4 CYHS2602567 地屈孕酮片江苏诺泰澳赛诺生物制药股份有限公司 4 CYHS2602566 雌二醇片北京金城泰尔制药有限公司 4 CYHS2602565 司美格鲁肽注射液广州白云山拜迪生物医药有限公司 3.3 CXSL2601141 司美格鲁肽注射液广州白云山拜迪生物医药有限公司 3.3 CXSL2601140 注射用盐酸兰地洛尔海南海灵化学制药有限公司 3 CYHS2602574 苹果酸奈诺沙星氯化钠注射液江西远超医药科技有限公司 4 CYHS2602573 他克莫司缓释胶囊国药集团川抗制药有限公司 4 CYHS2602572 他克莫司缓释胶囊国药集团川抗制药有限公司 4 CYHS2602571 阿伐那非片昆明积大制药股份有限公司 3 CYHS2602570 阿伐那非片昆明积大制药股份有限公司 3 CYHS2602569 聚乙二醇4000散成都医路康医学技术服务有限公司 4 CYHS2602568 盐酸乐卡地平片重庆华森制药股份有限公司 4 CYHS2602549 注射用多黏菌素E甲磺酸钠南京正科医药股份有限公司 3 CYHS2602551 四烯甲萘醌软胶囊南京海鲸药业股份有限公司 4 CYHS2602550 恩考芬尼胶囊齐鲁制药(海南)有限公司 4 CYHS2602556 贝美前列素滴眼液珠海前列药业有限公司 4 CYHS2602555 贝美前列素滴眼液珠海前列药业有限公司 4 CYHS2602554 盐酸利多卡因胶浆仁合益康汇泽药业河北有限公司 3 CYHS2602553 盐酸普萘洛尔口服溶液沈阳天邦药业有限公司 3 CYHS2602552 13价肺炎球菌多糖结合疫苗北京科兴中维生物技术有限公司 3.3 CXSS2600165 13价肺炎球菌多糖结合疫苗北京科兴中维生物技术有限公司 3.3 CXSS2600164 盐酸毛果芸香碱滴眼液海南斯达制药有限公司 3 CYHS2602548 醋酸钠林格注射液湖北长联杜勒制药有限公司 3 CYHS2602525 氯吡格雷阿司匹林片石药集团欧意药业有限公司 4 CYHS2602524 多替诺雷片湖南状元制药有限公司 4 CYHS2602523 多替诺雷片湖南状元制药有限公司 4 CYHS2602522 注射用托伐普坦磷酸钠湖北美林药业有限公司 4 CYHS2602534 注射用托伐普坦磷酸钠湖北美林药业有限公司 4 CYHS2602533 达格列净二甲双胍缓释片(I) 南京易亨制药有限公司 4 CYHS2602532 依折麦布辛伐他汀片江西施美药业股份有限公司 4 CYHS2602531 达格列净片江西施美药业股份有限公司 4 CYHS2602530 达格列净片江西施美药业股份有限公司 4 CYHS2602529 盐酸倍他司汀片海南药谷云生物科技有限公司 3 CYHS2602528 盐酸倍他司汀片海南药谷云生物科技有限公司 3 CYHS2602527 氧(液态) 宝武清能(广东)气体有限公司 4 CYHS2602526 茚达特罗格隆溴铵吸入粉雾剂北京抗创联生物制药技术研究有限公司 4 CYHL2600115 米诺地尔泡沫剂(女用) 浙江三生蔓迪药业有限公司 3 CYHS2602536 氯苯唑酸软胶囊上海奥科远制药有限公司 4 CYHS2602535 苯磺酸美洛加巴林片福建东瑞制药有限公司 4 CYHS2602540 苯磺酸美洛加巴林片福建东瑞制药有限公司 4 CYHS2602539 盐酸普萘洛尔口服溶液大玮(安徽)药业有限公司 3 CYHS2602538 戊酸雌二醇片株洲千金药业股份有限公司 4 CYHS2602537 依折麦布片浙江江北药业有限公司 4 CYHS2602544 左氧氟沙星滴眼液安徽省双科药业有限公司 4 CYHS2602543 酮洛芬贴剂深圳市康哲生物科技有限公司 3 CYHS2602542 酮洛芬贴剂深圳市康哲生物科技有限公司 3 CYHS2602541 酒石酸唑吡坦缓释片山东信谊制药有限公司 3 CYHL2600117 酒石酸唑吡坦缓释片山东信谊制药有限公司 3 CYHL2600116 盐酸非索非那定口服混悬液亚宝药业四川制药有限公司 3 CYHS2602547 苯磺酸左氨氯地平片新石阳光药业(河北)有限公司 4 CYHS2602546 苯磺酸左氨氯地平片新石阳光药业(河北)有限公司 4 CYHS2602545 多替诺雷片新石阳光药业(河北)有限公司 4 CYHS2602505 多替诺雷片新石阳光药业(河北)有限公司 4 CYHS2602504 雌二醇地屈孕酮片江苏诺泰澳赛诺生物制药股份有限公司 4 CYHS2602510 中性腹膜透析液(乳酸盐-G2.5%) 江苏杰瑞医疗技术有限公司 3 CYHS2602509 中性腹膜透析液(乳酸盐-G1.5%) 江苏杰瑞医疗技术有限公司 3 CYHS2602508 布立西坦片西南药业股份有限公司 3 CYHS2602507 乙酰半胱氨酸片江西迪赛诺医药集团有限公司 3 CYHS2602506 苯溴马隆片苏州第三制药厂有限责任公司 3 CYHS2602511 培哚普利氨氯地平片(III) 国药集团致君(深圳)制药有限公司 4 CYHS2602512 格隆溴铵注射液河南普瑞药业有限公司 3 CYHS2602516 格隆溴铵注射液河南普瑞药业有限公司 3 CYHS2602515 复方氨基酸注射液(18AA-VII) 山东豪瑞恩制药有限公司 4 CYHS2602514 甲钴胺片山东诺明康药物研究院有限公司 4 CYHS2602513 西吡氯铵含片北京四环科宝制药股份有限公司 3 CYHS2602521 注射用氟氧头孢钠云南先施药业有限公司 4 CYHS2602520 注射用氟氧头孢钠云南先施药业有限公司 4 CYHS2602519 沙库巴曲缬沙坦钠片北京康立生医药技术开发有限公司 4 CYHS2602518 沙库巴曲缬沙坦钠片北京康立生医药技术开发有限公司 4 CYHS2602517 色甘酸钠滴眼液成都普什制药有限公司 3 CYHS2602492 二硫化硒洗剂山东诺禾康药业有限公司 3 CYHS2602491 磷酸奥司他韦胶囊浙江亚太药业股份有限公司 4 CYHS2602490 马来酸噻吗洛尔滴眼液成都普什制药有限公司 3 CYHS2602494 马来酸噻吗洛尔滴眼液成都普什制药有限公司 3 CYHS2602493 美阿沙坦钾氯噻酮片北京福元医药股份有限公司 3 CYHL2600113 美阿沙坦钾氯噻酮片北京福元医药股份有限公司 3 CYHL2600112 别嘌醇片大桐制药(中国)有限责任公司 3 CYHS2602495 恩他卡朋双多巴片(II) 浙江华海药业股份有限公司 4 CYHS2602499 尿素[14C]胶囊湖南赛利斯医学生物科技有限公司 3 CYHL2600114 玻璃酸钠滴眼液广东南国药业有限公司 4 CYHS2602498 沙美特罗替卡松吸入粉雾剂润生药业有限公司 4 CYHS2602496 玻璃酸钠滴眼液广东南国药业有限公司 4 CYHS2602497 富马酸依美斯汀缓释胶囊广州绿十字制药股份有限公司 3 CYHS2602503 富马酸依美斯汀缓释胶囊广州绿十字制药股份有限公司 3 CYHS2602502 注射用盐酸苯达莫司汀广州白云山明兴制药有限公司 4 CYHS2602501 注射用盐酸苯达莫司汀广州白云山明兴制药有限公司 4 CYHS2602500进口申请药品名称企业注册分类受理号 Ferric Bepectate IV Injection AFT Pharmaceuticals Ltd 1 JXHL2600456 Ferric Bepectate IV Injection AFT Pharmaceuticals Ltd 1 JXHL2600455 Ferric Bepectate IV Injection AFT Pharmaceuticals Ltd 1 JXHL2600454 ABBV-253注射用粉末 AbbVie Inc. 1 JXSL2600278 ALXN1720注射液 Alexion Pharmaceuticals, Inc. 1 JXSL2600277 依非兰诺片 Ipsen Biopharmaceuticals 5.1 JXHS2600130 DDY391片 Novartis Pharma AG 1 JXHL2600457 Momelotinib 片 GlaxoSmithKline Research & Development Limited 2.4 JXHL2600460 Momelotinib 片 GlaxoSmithKline Research & Development Limited 2.4 JXHL2600459 Momelotinib 片 GlaxoSmithKline Research & Development Limited 2.4 JXHL2600458 SAR447998注射用浓溶液 Sanofi-Aventis Recherche & Developpement 1 JXSL2600280 SAR447998注射用浓溶液 Sanofi-Aventis Recherche & Developpement 1 JXSL2600279 Tilrekimig注射液 Pfizer Inc. 1 JXSL2600276 ASP2138注射液 Astellas Pharma Global Development, Inc. 1 JXSL2600275 Alnuctamab注射液 Bristol-Myers Squibb Company 1 JXSL2600274 Alnuctamab注射液 Bristol-Myers Squibb Company 1 JXSL2600273 塔奎妥单抗注射液 Janssen-Cilag International NV 2.2 JXSS2600097 塔奎妥单抗注射液 Janssen-Cilag International NV 2.2 JXSS2600096 注射用A型肉毒毒素 NUMECO Inc. 3.4 JXSL2600272 Retatrutide注射液 Eli Lilly and Company 1 JXHL2600453 Retatrutide注射液 Eli Lilly and Company 1 JXHL2600452 Retatrutide注射液 Eli Lilly and Company 1 JXHL2600451 Retatrutide注射液 Eli Lilly and Company 1 JXHL2600450 非唑奈坦片 Astellas Pharma Europe B.V. 5.1 JXHS2600129 来瑞奇珠单抗注射液(皮下注射) Eli Lilly and Company 2.2 JXSS2600095 瑞利珠单抗注射液 Alexion Europe SAS 2.2 JXSS2600093 瑞利珠单抗注射液 Alexion Europe SAS 2.2 JXSS2600092 尼塔奇单抗注射液(皮下注射) JSC BIOCAD 3.1 JXSS2600094 BI 456906 注射液 Boehringer Ingelheim International GmbH 1 JXHL2600448 BI 456906 注射液 Boehringer Ingelheim International GmbH 1 JXHL2600447 BI 456906 注射液 Boehringer Ingelheim International GmbH 1 JXHL2600446 BI 456906 注射液 Boehringer Ingelheim International GmbH 1 JXHL2600445 BI 456906 注射液 Boehringer Ingelheim International GmbH 1 JXHL2600444 BI 456906 注射液 Boehringer Ingelheim International GmbH 1 JXHL2600443 BI 456906 注射液 Boehringer Ingelheim International GmbH 1 JXHL2600442 GVV858 Novartis Pharma AG 1 JXHL2600441 Fenebrutinib片 F. Hoffmann-La Roche Ltd. 1 JXHL2600439 LY5830966片 Ajax Therapeutics, Inc. (a wholly owned subsidiary of Eli Lilly and Company) 1 JXHL2600440 LY888891混悬液 Eli Lilly and Company 1 JXSL2600270 泰它西普注射液 Vor Biopharma Inc. 2.2 JXSL2600271 法瑞西单抗注射液 Roche Pharma (Schweiz) AG 2.2 JXSS2600091 法瑞西单抗注射液 Roche Pharma (Schweiz) AG 2.2 JXSS2600090中药相关申请药品名称企业注册分类受理号保济口服液广州王老吉药业股份有限公司 2.3 CXZL2600103 金莲咽扁颗粒广州博济新药临床研究中心有限公司 1.1 CXZL2600102 达瓦依鲁克蜜丸新疆维吾尔自治区维吾尔医医院(新疆维吾尔自治区第二人民医院) 1.1 CXZL2600104 健骨关节颗粒北京以岭药业有限公司 1.1 CXZL2600106 JSBCPZ001颗粒北京创立科创医药技术开发有限公司 1.1 CXZL2600105 济川煎颗粒合肥华润神鹿药业有限公司 2.3 CXZL2600101 金花清感颗粒聚协昌(北京)药业有限公司 2.3 CXZS2600055 易黄汤颗粒贵阳新天药业股份有限公司 3.1 CXZS2600056 芍药甘草汤颗粒江苏康缘药业股份有限公司 3.1 CXZS2600054 四季抗病毒合剂安徽神农百草药业有限公司 4 CYZL2600002 金菊消痤颗粒重庆希尔安药业有限公司 1.1 CXZL2600100 健脑通络颗粒武汉博锦泰科技有限公司 1.1 CXZL2600099 半夏白术天麻汤颗粒神威药业集团有限公司 3.1 CXZS2600053 消炎解毒合剂湖北一恩药业有限公司 2.2 CXZL2600098 注：绿色字体部分为潜在首仿品种；橙色字体部分结论为不批准或收到通知件；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市临床申请

2026-10-19

·ioncology

ESMO Asia 2026丨瞭望前瞻，42项中国乳腺癌研究闪耀狮城，不止参与，更是主角

点击上方蓝字关注我们编者按：2026年欧洲肿瘤内科学会亚洲年会（ESMO Asia 2026）将于2026年12月4日至6日举办，本次会议是亚太地区肿瘤学领域的年度学术盛会，旨在汇聚全球顶尖专家，分享前沿科研成果与临床实践智慧。目前会议入选研究标题已正式公布，其中乳腺癌领域共有42项中国研究入选，涵盖4项口头报告及38项壁报，《肿瘤瞭望》特将研究信息整理如下，以供参考，如有疏漏，敬请留言指正。 Proffered Paper（优选口头报告）摘要号：3O 英文标题：Neoadjuvant trastuzumab deruxtecan followed by paclitaxel + trastuzumab +pertuzumab (T-DXd-THP) vs dose-dense doxorubicin + cyclophosphamide followed byTHP (ddAC-THP) in East Asian patients with high-risk, HER2+ early-stage breast cancer(eBC): A DESTINY-Breast11 (DB-11) analysis 中文标题：高危HER2阳性早期乳腺癌东亚患者新辅助T-DXd序贯THP对比剂量密集ddAC序贯THP：DESTINY-Breast11（DB-11）研究分析讲者：吴炅复旦大学附属肿瘤医院时间：Fri,Dec4,2026 11:23-11:33 地点：Hall 401 摘要号：4O 英文标题：Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts)from Asia with human epidermal growth factor receptor 2-positive (HER2+) residualinvasive early breast cancer (eBC) after neoadjuvant therapy (NAT): DESTINY-Breast05(DB-05) subgroup analysis 中文标题：新辅助治疗后HER2阳性残留浸润性早期乳腺癌亚洲患者T-DXd对比T-DM1：DESTINY-Breast05（DB-05）研究亚组分析讲者：黄俊升台湾大学医学院附设医院时间：Fri,Dec4,2026 11:33-11:43 地点：Hall 401 Rapid Oral（快速口头报告）摘要号：95RO 英文标题：First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patientswith locally recurrent inoperable or metastatic triple-negative breast cancer for whomimmunotherapy was not an option: Results from the TROPION-Breast02 Chinese cohort 中文标题：Dato-DXd对比化疗用于免疫治疗不可用的局部复发不可手术或转移性三阴性乳腺癌一线治疗：TROPION-Breast02研究中国队列结果讲者：邵志敏复旦大学附属肿瘤医院时间：Sat,Dec5,2026 14:35-14:40 地点：Hall 401 摘要号：99RO 英文标题：Trastuzumab deruxtecan plus pyrotinib in first-line HER2-positive unresectable ormetastatic breast cancer: interim analysis of the TROPHY study 中文标题：T-DXd联合吡咯替尼一线治疗HER2阳性不可切除或转移性乳腺癌：TROPHY研究中期分析讲者：樊英中国医学科学院肿瘤医院时间：Sat,Dec5,2026 15:22-15:27 地点：Hall 401 Poster&ePoster（壁报及电子壁报）摘要号：10P 英文标题：Prognostic Analysis of De-escalated Axillary Surgery in HR+/HER2−, cN0 BreastCancer Patients Undergoing Breast-Conserving Surgery 中文标题：HR+/HER2-、cN0期保乳乳腺癌患者腋窝手术降阶梯的预后分析讲者：Luning Yang (Kunming, CN) 摘要号：13P 英文标题：Standard imaging-guided, Doppler-free chest wall perforator flap reconstruction forgranulomatous lobular mastitis: A simplified approach for resource-limited settings 中文标题：标准影像引导无多普勒胸壁穿支皮瓣重建治疗肉芽肿性小叶性乳腺炎：一种适用于资源有限场景的简化方案讲者：Ziying Wang (Nanjing, CN) 摘要号：15P 英文标题：Real-World Study: Prognosis and Quality of Life Assessment of Breast CancerPatients Undergoing Breast-Conserving Surgery and Total Mastectomy in Xinjiang Region 中文标题：真实世界研究：新疆地区乳腺癌患者保乳手术与全乳切除术后的预后及生活质量评估讲者：Shengjie Liu (Urumqi, CN) 摘要号：18P 英文标题：Non-estradiol hormonal profiling reveals pituitary-axis activation patterns beyondestradiol suppression during GnRHa plus exemestane therapy 中文标题：非雌二醇激素谱揭示GnRHa联合依西美坦治疗中超出雌二醇抑制的垂体轴激活模式讲者：薛聪中山大学肿瘤防治中心摘要号：20P 英文标题：Health-related quality of life (HRQoL) with adjuvant dalpiciclib plus endocrine therapyin patients with hormone receptor-positive (HR+), HER2-negative (HER2–), earlyintermediate-to-high-risk breast cancer: Results from a multicenter, two-cohort phase 2trial 中文标题：达尔西利联合内分泌治疗辅助治疗HR+/HER2-早期中高危乳腺癌患者的健康相关生活质量：一项多中心、双队列II期试验结果讲者：徐贵颖吉林省肿瘤医院摘要号：27P 英文标题：Real-world perioperative treatment patterns for HER2+ early-stage breast cancer(eBC) in China 中文标题：中国HER2阳性早期乳腺癌围手术期治疗模式的真实世界研究讲者：王佳玉中国医学科学院肿瘤医院摘要号：32P 英文标题： Neoadjuvant Pyrotinib Monotherapy in HER2-Positive Ductal Carcinoma In Situ: APhase II Single-Arm Study 中文标题：新辅助吡咯替尼单药治疗HER2阳性导管原位癌：一项II期单臂研究讲者：何佳玲陆军军医大学西南医院摘要号：35P 英文标题：Targeting DDX5 with tetraarsenic tetrasulfide overcomes cisplatin resistance intriple-negative breast cancer 中文标题：四硫化四砷靶向DDX5逆转三阴性乳腺癌顺铂耐药讲者：Zhiyi Liu (Shanghai, CN) 摘要号：43P 英文标题：Expression Patterns, Prognostic Values and Underlying Mechanisms of Diabetes-Related Genes in Breast Cancer 中文标题：糖尿病相关基因在乳腺癌中的表达模式、预后价值及作用机制讲者：Yu Zhou (Fuzhou, CN) 摘要号：46P 英文标题：Harnessing Frequency-Aware Deep Architectures and Hybrid Feature Fusion forRobust Rare Cell Identification in Clinical Fluorescence Microscopy 中文标题：基于频率感知深度架构与混合特征融合的临床荧光显微罕见细胞精准识别讲者：Jiao-Mei Gong (Zhengzhou, CN) 摘要号：55eP 英文标题：World Effectiveness of Abemaciclib in Chinese Patients with Breast Cancer: A2‑Year Follow‑Up 中文标题：阿贝西利在中国乳腺癌患者中的真实世界疗效：2年随访结果讲者：刘强中山大学孙逸仙纪念医院摘要号：56eP 英文标题：PIK3CA mutation spectrum and clinicopathological associations in early-stagehormone receptor-positive breast cancer: an interim analysis 中文标题：早期HR阳性乳腺癌PIK3CA突变谱与临床病理特征的关联：中期分析讲者：颜蕴文安徽医科大学第一附属医院摘要号：60eP 英文标题：Genomic Drivers and Prognostic Biomarkers in Breast Cancer: Insights from Large-Scale Sequencing Cohorts 中文标题：乳腺癌基因组驱动因素与预后生物标志物：来自大规模测序队列的启示讲者：Longyan Xie (Shanghai, CN) 摘要号：68P 英文标题：Total examined axillary lymph nodes as an independent predictor of pathologicalcomplete response after neoadjuvant therapy in ER+/HER2– breast cancer: a retrospectivemulticenter analysis 中文标题：腋窝淋巴结清扫总数作为ER+/HER2-乳腺癌新辅助治疗后病理完全缓解的独立预测因素：一项回顾性多中心分析讲者：吕文杰上海交通大学医学院附属新华医院摘要号：77P 英文标题：Deep Learning for Early Prediction of Breast Cancer Response to NeoadjuvantTherapy Using Dynamic Contrast-enhanced Ultrasound Videos 中文标题：基于动态对比增强超声视频的深度学习早期预测乳腺癌新辅助治疗疗效讲者：Liting Feng (Chengdu, CN) 摘要号：85P 英文标题：Interpretable CoxPH-centered machine learning models for predicting cancer-specific survival and treatment-associated survival patterns in stage II-III triple-negativebreast cancer 中文标题：基于可解释CoxPH的机器学习模型预测II-III期三阴性乳腺癌肿瘤特异性生存及治疗相关生存模式讲者：Sirui Zhu (Beijing, CN) 摘要号：104P 英文标题：Real-World Effectiveness and Safety of Inavolisib-Based Therapy in Chinese Patients with HR+/HER2− Advanced Breast Cancer: A Multicenter Study 中文标题：伊那利塞为基础的方案治疗中国HR+/HER2-晚期乳腺癌患者的真实世界疗效与安全性：一项多中心研究讲者：梁旭北京大学肿瘤医院摘要号：106P 英文标题：Baseline genomic landscape associated with early progression during first-lineCDK4/6 inhibitor-based endocrine therapy in HR+/HER2− metastatic breast cancer: anexploratory whole-exome sequencing study 中文标题：HR+/HER2-转移性乳腺癌一线CDK4/6抑制剂联合内分泌治疗早期进展相关的基线基因组图谱：一项探索性全外显子测序研究讲者：杨庄青云南省肿瘤医院摘要号：108P 英文标题：Real‑world effectiveness and safety of Dalpiciclib in elderly patients with hormonereceptor‑positive advanced breast cancer: a multi-center retrospective study 中文标题：达尔西利治疗老年HR阳性晚期乳腺癌患者的真实世界疗效与安全性：一项多中心回顾性研究讲者：Mengran Xu (Hefei, CN) 摘要号：111P 英文标题：Real-World Efficacy and Safety of Inavolisib Combined with Various CDK4/6Inhibitors in PIK3CA-Mutated, HR+/HER2− Advanced Breast Cancer 中文标题：伊那利塞联合不同CDK4/6抑制剂治疗PIK3CA突变HR+/HER2-晚期乳腺癌的真实世界疗效与安全性讲者：农巧红北京大学深圳医院摘要号：112P 英文标题：Real-World analysis of Inavolisib-based therapy in advanced breast cancer patientswith PIK3CA mutations in China 中文标题：伊那利塞为基础的方案治疗中国PIK3CA突变晚期乳腺癌患者的真实世界分析讲者：宋玉华青岛大学附属医院摘要号：115P 英文标题：Real-world data on safety of switching to trastuzumab rezetecan after discontinuation of other HER2-directed antibody-drug conjugates, primarily trastuzumab deruxtecan, due to adverse events in advanced HER2-positive/low breast cancer 中文标题：晚期HER2阳性/低表达乳腺癌患者因不良事件停用其他靶向HER2 ADC（主要为T-DXd）后换用瑞康曲妥珠单抗的安全性真实世界数据讲者：欧阳取长湖南省肿瘤医院摘要号：116P 英文标题：Early dynamic ⁶⁸Ga-HER2 PET/CT for predicting clinical benefit of anti-HER2 therapyin advanced HER2-positive breast cancer: Head-to-head comparison with RECIST 1.1 and¹⁸F-FDG PET/CT 中文标题：早期动态⁶⁸Ga-HER2 PET/CT预测晚期HER2阳性乳腺癌抗HER2治疗临床获益：与RECIST1.1及¹⁸F-FDG PET/CT的头对头比较讲者：缪海韬复旦大学附属肿瘤医院摘要号：119P 英文标题：Real-world study of different anti-HER2 treatment strategies in first-line HER2-positive advanced breast cancer 中文标题：HER2阳性晚期乳腺癌一线不同抗HER2治疗策略的真实世界研究讲者：Yuqing Chen (Kunming, CN) 摘要号：120P 英文标题：Trop-2 Expression Level and Efficacy of Trop-2–Targeted Antibody–DrugConjugates in Patients With Advanced Breast Cancer: A Systematic Review and Meta-Analysis 中文标题：晚期乳腺癌患者Trop-2表达水平与靶向Trop-2 ADC疗效的相关性：一项系统评价与荟萃分析讲者：彭上轩台湾大学医学院附设医院云林分院摘要号：121P 英文标题：Predictive value of obesity and serum non-esterified fatty acid (NEFA) in patientswith metastatic triple-negative breast cancer receiving PD-1 blockade 中文标题：肥胖及血清非酯化脂肪酸对接受PD-1抑制剂治疗的转移性三阴性乳腺癌患者的预测价值讲者：Yizhao Xie (Shanghai, CN) 摘要号：122P 英文标题：Survival improvement in the immune checkpoint inhibitor-introduction era andresidual prognostic value of lymph node burden in triple-negative breast cancer 中文标题：免疫检查点抑制剂时代三阴性乳腺癌的生存改善及淋巴结负荷的残留预后价值讲者：Linjie Fan (Beijing, CN) 摘要号：123P 英文标题：A Lactate–Lactylation Decoupling Program Silences AKR1C1 via HDAC1 to DriveCisplatin Resistance in Triple-Negative Breast Cancer 中文标题：乳酸-乳酸化失偶联程序通过HDAC1沉默AKR1C1介导三阴性乳腺癌顺铂耐药讲者：Yawei Zhao (Shanghai, CN) 摘要号：124P 英文标题：Upfront versus delayed radiotherapy in breast cancer brain metastases: A real-world cohort study 中文标题：乳腺癌脑转移患者即刻与延迟放疗的对比：一项真实世界队列研究讲者：Hang Zao (Urumqi, CN) 摘要号：128P 英文标题：RALA-RALBP1 axis activates endothelial RAC1/NF-κB signaling to promote breastcancer metastasis 中文标题：RALA-RALBP1轴通过激活内皮细胞RAC1/NF-κB信号通路促进乳腺癌转移讲者：Qian Huang (Xi'an, CN) 摘要号：131P 英文标题：Tetrastigma hemsleyanum polysaccharide suppresses breast cancer stem cells-driven metastatic by targeting the CDCP1/NF-κB/NACC1 axis 中文标题：三叶青多糖通过靶向CDCP1/NF-κB/NACC1轴抑制乳腺癌干细胞介导的转移讲者：Si Wentao (Nanjing, CN) 摘要号：133P 英文标题： Identification of E3 Ubiquitin Ligase-Related Genes in Triple-Negative Breast Cancerand Analysis of Their Regulatory Networks and Clinical Implications 中文标题：三阴性乳腺癌E3泛素连接酶相关基因的鉴定及其调控网络与临床意义分析讲者：Yu Zhou (Fuzhou, CN) 摘要号：137TiP 英文标题：A Prospective, Non-Randomized, Open-Label Phase Single-Arm Study of First-Line Low-Dose Nab-Paclitaxel in Combination with Toripalimab and FractionatedStereotactic Radiotherapy (FSRT) for Triple-Negative Breast Cancer with Brain Metastasis 中文标题：低剂量白蛋白紫杉醇联合特瑞普利单抗及分次立体定向放疗一线治疗三阴性乳腺癌脑转移：一项前瞻性、非随机、开放标签单臂研究讲者：范宇西南医科大学附属医院摘要号：138TiP 英文标题：Metronomic Vinorelbine Chemotherapy Combined with Penpulimab and Local Radiotherapy (Hypofractionated Radiotherapy or SBRT/FSRT), With or Without Anlotinib,for Recurrent/Metastatic Triple-Negative Breast Cancer: A Prospective, Single-Arm Study 中文标题：长春瑞滨节拍化疗联合派安普利单抗及局部放疗（大分割放疗或SBRT/FSRT）±安罗替尼治疗复发/转移性三阴性乳腺癌：一项前瞻性单臂研究讲者：范宇西南医科大学附属医院摘要号：140eP 英文标题：PIK3CA-mutated HR+/HER2– advanced breast cancer: A pharmacist-ledmulticenter retrospective observational study 中文标题：PIK3CA突变HR+/HER2-晚期乳腺癌：一项药师主导的多中心回顾性观察性研究讲者：李曼大连医科大学附属第二医院摘要号：142eP 英文标题：Pyrotinib plus dalpiciclib and letrozole in ER-positive/HER2-positive advancedbreast cancer: updated phase II results 中文标题：吡咯替尼联合达尔西利及来曲唑治疗ER阳性/HER2阳性晚期乳腺癌：II期研究更新结果讲者：陈占红浙江省肿瘤医院摘要号：693P 英文标题：Immunometabolic Features and Potential Clinical Value of Ferroptosis–Nucleic AcidMetabolism Coupling in Triple-Negative Breast Cancer 中文标题：三阴性乳腺癌铁死亡-核酸代谢偶联的免疫代谢特征及潜在临床价值讲者：He Hao (Taiyuan, CN) 摘要号：711eP 英文标题：Multi-omics Integration Reveals a Novel Synergistic Anti-Breast Cancer Mechanism of Trastuzumab Deruxtecan Combined with Lapatinib 中文标题：多组学整合揭示T-DXd联合拉帕替尼抗乳腺癌的新型协同作用机制讲者：Yijun Li (Xi'an, CN) 摘要号：726eP 英文标题：Preclinical evaluation and target characterization of cyclic peptide C5 in triple-negative breast cancer 中文标题：环肽C5在三阴性乳腺癌中的临床前评价及靶点表征讲者：Qichen Dai (Beijing, CN) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

2026-10-18

·Science Daily

Scientists discover that male and female skin play by different rules

Scientists have uncovered a surprising difference in how male and female skin repairs and renews itself. By tracking individual skin stem cells in living mice for five months, researchers discovered that female cells work together in a highly coordinated way, while male cells operate more independently. This synchronization, driven by sex hormones, helps explain why wounds heal faster in female mice, especially during the first few days.Female mice heal skin wounds faster than males, and scientists have uncovered a surprising biological difference that may help explain why. By watching skin stem cells in living mice for five months, researchers found that female cells work together in a more coordinated way, while male cells tend to behave more independently. These differences are regulated by sex hormones and could eventually help scientists develop more personalized treatments for wound healing and skin diseases. The discovery comes from researchers at the Université libre de Bruxelles (ULB), working with scientists at the University of Cambridge. Their findings suggest that biological sex influences how skin renews and repairs itself, even though the skin is not part of the reproductive system. Historically, much of the research into biological differences between males and females has focused on reproductive organs. However, sex can also influence other tissues and organs throughout the body. Understanding these differences could be important for improving the prevention and treatment of inflammatory diseases and cancer, yet researchers have often overlooked their significance. Published in Nature, the study was led by Prof. Cédric Blanpain, MD/PhD, an investigator at the WEL Research Institute, director of the Laboratory of Stem Cells and Cancer, and professor at the Université libre de Bruxelles. The research was conducted in collaboration with Prof. Benjamin Simons and his team at the University of Cambridge, along with scientists from several other institutions. Using an advanced microscopy technique, the researchers were able to record individual cells through the skin of living mice. This allowed them to follow the same stem cells and their descendants for five months, an unprecedented period of observation. Although their original goal was to understand the mechanisms behind skin renewal, the team unexpectedly discovered striking differences between females and males. Further experiments revealed that sex hormones were responsible. How Skin Stem Cells Renew the Skin The skin's outermost layer is constantly replacing itself. This process begins with stem cells located at the bottom of the layer, where they divide to produce new cells. Some of the resulting "daughter" cells retain their ability to function as stem cells, while others begin developing into specialized cells. These specialized cells form the protective barrier that shields the body from its surroundings. As they mature, they lose the ability to divide (a process called differentiation), gradually move toward the surface, and are eventually shed. Scientists have debated the precise organization of this renewal process for decades. By repeatedly observing the same areas of skin over five months, the researchers found that stem cells do not immediately become fully mature skin cells. Instead, they pass through an intermediate stage in which they can divide only a limited number of times before completing their development into specialized cells. This finding helps clarify a long-standing question about how the skin maintains itself. Female Skin Cells Work in Surprising Synchronization One of the most unexpected findings involved the behavior of newly formed cells. In female mice, two "sister" cells produced by the division of a single parent cell frequently make the same developmental decision at the same time. Both may divide again, or both may begin specializing into mature skin cells. Their behavior resembles two rowers moving their oars in unison. In male mice, however, sister cells are less closely synchronized and tend to follow more independent patterns. "We initially set out to understand how the skin renews itself, and whether there is a hierarchy with stem cells at the top. We were surprised to discover strong differences in the way stem cells renew the skin in females and males," explains Doctor Dan Engelman, the first author of the study. Sex Hormones Control How Skin Cells Behave To determine what caused these differences, the scientists investigated the influence of male and female sex hormones. They first examined what happened when male mice were castrated, removing the primary source of testosterone. Without this hormone, their skin cells began behaving more like those in females. When the researchers administered dihydrotestosterone (DHT), an active form of testosterone, the cells returned to their typical male pattern. These experiments showed that male sex hormones help regulate how rapidly skin cells mature and move out of the stem cell layer. The team also investigated the role of female sex hormones. Removing the ovaries (ovariectomy) reduced the rate at which stem cells multiplied and almost completely eliminated the characteristic synchronization between sister cells. Treatment with estradiol, a form of estrogen, reversed the reduction in stem cell proliferation. Together, these findings revealed that testosterone, which is generally more abundant in males, influences the speed of skin cell maturation. Estrogens, which are generally more abundant in females, promote stem cell proliferation and help coordinate the behavior of newly produced cells. The researchers also tested testosterone on human skin reconstructed in the laboratory. They found that the hormone accelerated stem cell differentiation, suggesting that at least part of the mechanism observed in mice may also operate in humans. Why Skin Wounds Heal Faster in Female Mice The differences in stem cell behavior were accompanied by another important finding: female mice recovered more quickly from skin injuries. When researchers examined wounds on the animals' backs, they found that wounds closed substantially faster in females, particularly during the first few days after injury. This early advantage was partly associated with skin stem cells becoming active sooner and working in a more coordinated manner. As healing progressed, the difference between males and females gradually became smaller. The results suggest that the hormonal regulation of stem cells may help explain why skin repair differs between the sexes. What the Discovery Could Mean for Wound Healing and Skin Cancer Doctors have long recognized differences between men and women in wound healing, the severity of certain inflammatory conditions, and the frequency of some skin cancers. However, the underlying biological explanations have remained incomplete. By identifying how sex hormones influence stem cell activity, the new research provides a possible explanation for some of these observations. The findings could eventually contribute to medical treatments that account for a patient's sex. Potential applications include improving recovery from burns and surgery, as well as treating chronic wounds in people with diabetes, a problem affecting millions worldwide. Understanding these differences may also help researchers develop new approaches to preventing skin cancer, one of the most common forms of cancer. For now, faster wound healing and coordinated stem cell behavior were demonstrated in mice. Additional research will be needed to determine how closely these processes match those in human skin and whether they can be used to improve medical care. Beyond their potential clinical importance, the findings also provide new insight into the fundamental process of skin renewal, helping address a question that has challenged scientists for decades. "This study is a technological tour de force, and the discovery of differences between male and female skin stem cells is fascinating and entirely unexpected. It sheds light on a series of clinical observations that previously lacked a biological explanation. It opens up a wide range of new questions, spanning from fundamental stem cell biology to clinical issues such as wound healing, cancer development, and autoimmune diseases. Sex is a parameter too often overlooked in biology and medicine. We will now investigate the differences between males and females during the formation and progression of skin cancers, as well as the molecular mechanisms responsible for these differences," says Prof. Cédric Blanpain, who led the study. Research Collaborations and Funding The project brought together Prof. Blanpain's team (ULB, Belgium) and Prof. Simons' group (University of Cambridge, UK), along with research teams led by Michele De Luca (University of Modena and Reggio Emilia, Italia), Yulia Shwartz (Broad CIRM Center, University of Southern California, Los Angeles, US) and Esther Hoste (VIB-Ghent University, Belgium). Funding was provided by the FNRS (including FRIA fellowships), TELEVIE, the WEL Research Institute, the Fondation contre le Cancer, the Fondation ULB, the Fonds Erasme, the Fondation Julie et Françoise Drion, the Fonds Yvonne Boël, the joint FNRS/FWO EOS (Excellence of Science) program and the European Research Council (ERC).

100 项与戊酸雌二醇相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01413	戊酸雌二醇	G03CA03	DB13956

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
女性不孕症	日本	Fuji Pharma Co., Ltd.	2008-03-07
卵巢功能不全	日本	Fuji Pharma Co., Ltd.	2008-03-07
子宫出血	日本	Fuji Pharma Co., Ltd.	2008-03-07
雌激素缺乏症状	中国	华中药业股份有限公司	1983-01-01
闭经	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
更年期	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
痛经	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
月经过少	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
不孕	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
月经过多	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
月经紊乱	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
子宫不规则出血	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
卵巢疾病	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
子宫疾病	日本	Mochida Pharmaceutical Co., Ltd.	1954-11-01
低雌激素	美国	PH HEALTH	1954-07-15
前列腺癌	美国	PH HEALTH	1954-07-15
血管舒缩症	美国	PH HEALTH	1954-07-15
外阴和阴道萎缩	美国	PH HEALTH	1954-07-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06253702 (CTgov)	临床4期	脑血管疾病	22	Orilissa+estradiol (Female Participants Placebo First)	鑰簾願廠積繭醖艱淵鑰(餘鏇蓋艱選衊網網顧選) = 鏇選願顧衊遞艱壓築選積鏇窪範獵廠膚獵艱糧 (艱構鹽壓製鑰襯願鬱鹽, 9.35) 更多	-	2026-09-24
				Orilissa+estradiol (Female Participants Indo First)	鑰簾願廠積繭醖艱淵鑰(餘鏇蓋艱選衊網網顧選) = 齋窪蓋繭觸願鏇獵築構積鏇窪範獵廠膚獵艱糧 (艱構鹽壓製鑰襯願鬱鹽, 15.88) 更多
NCT06005610 (GETITRIgHT, CTgov)	临床2期	HIV感染	93	Estradiol (Group 1: Estradiol Among BIC-treated)	觸襯壓鑰鑰夢膚選襯餘 = 壓衊餘夢簾襯範網艱築鬱淵願繭蓋膚獵夢膚範 (構糧窪齋艱構鏇簾憲齋, 淵衊構餘淵膚願艱醖醖 ~ 顧繭糧獵艱齋艱淵壓窪) 更多	-	2026-04-08
				Estradiol (Group 2: Estradiol Among DTG-treated)	觸襯壓鑰鑰夢膚選襯餘 = 顧淵鏇壓憲網遞範淵鑰鬱淵願繭蓋膚獵夢膚範 (構糧窪齋艱構鏇簾憲齋, 艱獵憲淵窪範襯繭遞餘 ~ 夢糧鹽膚獵糧築糧醖膚) 更多
NCT04760691 (CTgov)	临床1期	HIV感染	13	Truvada alone (Pre-Exposure Prophylaxis (PrEP) Only)	壓襯繭鏇齋網網網艱獵(範鏇壓憲積蓋遞壓艱構) = 壓鬱窪簾繭憲齋蓋壓顧膚壓獵鹹憲積願襯繭衊 (遞簾積壓築願衊網壓鬱, 憲網蓋鹽淵鬱獵製衊鏇 ~ 窪製範築餘淵艱積壓夢) 更多	-	2026-04-03
				Truvada+Leuprolide (PrEP Plus Gonadotropin Releasing Hormone (GnRH) Agonist)	壓襯繭鏇齋網網網艱獵(範鏇壓憲積蓋遞壓艱構) = 製餘鬱構鬱網糧蓋衊顧膚壓獵鹹憲積願襯繭衊 (遞簾積壓築願衊網壓鬱, 觸觸觸糧範淵選窪淵憲 ~ 積鏇構膚餘醖膚獵構積) 更多
AAD2026	N/A	皮肤老化	760	Estradiol	鹽壓簾鹽範網壓夢醖選(鏇鏇鑰選範窪築遞壓觸) = sensitivity (4.4%), seborrhea (1.5%), rash (1.5%), pigmentation (2.9%), breast pain (6.7%), vaginal bleeding (0.7%), increased breast volume (0.7%) 廠鬱廠觸窪範鹹顧獵繭 (憲願齋繭鹽鏇壓鹹積繭 ) 更多	积极	2026-03-27
NCT04192266 (CTgov)	临床3期	创伤后应激障碍	83	Prolonged Exposure (PE) therapy+Estradiol (Prolonged Exposure (PE) Therapy With Estradiol)	網衊網鏇範選淵築襯糧(繭簾製獵襯醖獵窪簾繭) = 積醖鏇遞顧壓衊顧窪膚淵糧鹽鏇製餘製鹽積觸 (衊積觸蓋築衊鹽艱範艱, 0.201) 更多	-	2026-01-09
				Placebo oral tablet (Prolonged Exposure (PE) Therapy With Placebo)	網衊網鏇範選淵築襯糧(繭簾製獵襯醖獵窪簾繭) = 願遞鑰簾繭憲糧窪顧憲淵糧鹽鏇製餘製鹽積觸 (衊積觸蓋築衊鹽艱範艱, 0.159) 更多
NCT00001481 (CTgov)	临床2期	产后抑郁症	74	placebo+gonadotropin releasing hormone (GnRH) agonist leuprolide acetate (Lupron)+progesterone (Arm 1a - Postpartum Depression: Hormone Withdrawal)	廠窪壓艱願壓製繭獵艱(壓願鬱襯築顧繭鏇蓋醖) = 壓鬱選鑰鏇鑰鏇積構齋憲積積積艱簾繭築襯鬱 (積積醖觸鹽願憲網鹹築, 6.32) 更多	-	2025-12-05
				placebo+progesterone (Arm 1b - Depression, Non-reproductive: Hormone Withdrawal)	廠窪壓艱願壓製繭獵艱(壓願鬱襯築顧繭鏇蓋醖) = 衊範淵簾構簾範餘鑰淵憲積積積艱簾繭築襯鬱 (積積醖觸鹽願憲網鹹築, NA) 更多
NCT05388656 (CTgov)	临床4期	情绪易怒	40	estradiol (Estradiol)	築鬱襯壓範顧鑰顧觸壓(獵顧觸築鑰鬱衊積壓願) = 壓觸蓋壓鑰遞糧範觸選簾獵鹹鬱鏇糧蓋窪積範 (壓鏇構窪製鹽廠選憲艱, 1.33) 更多	-	2025-11-26
				placebo+estradiol (Placebo)	築鬱襯壓範顧鑰顧觸壓(獵顧觸築鑰鬱衊積壓願) = 醖壓醖窪簾顧艱淵衊餘簾獵鹹鬱鏇糧蓋窪積範 (壓鏇構窪製鹽廠選憲艱, 1.02) 更多
ESPE2025	N/A	代谢综合征	438	Masculinizing hormone therapy (treatment naïve)	範醖鏇艱鏇淵廠簾遞鏇(糧廠艱鬱糧鏇齋膚鏇衊) = 獵窪鹹繭鏇窪簾夢鹹願窪鬱窪壓願鏇餘窪選糧 (繭構衊選選獵憲淵網構 ) 更多	不佳	2025-05-10
				Feminizing hormone therapy (treatment naïve)	糧鏇繭餘糧衊齋壓憲顧(簾窪淵鹽構網鑰繭選顧) = 範積齋顧觸願遞鑰選襯鑰構蓋夢齋獵窪遞醖衊 (積艱糧餘壓顧顧獵遞鏇 )
NCT04036500 (CTgov)	早期临床1期	-	11	Estradiol	壓鏇餘繭鑰鬱鏇壓顧鬱(淵觸夢醖淵積憲製鏇餘) = 築遞夢艱淵膚餘醖鹽壓繭鏇鹽鑰憲觸網醖襯繭 (膚積獵選範選獵築觸艱, 90) 更多	-	2025-04-01
NCT04283656 (IDENTIFY, CTgov)	临床1期	HIV感染	8	Spironolactone 100mg+Estradiol 2mg+Doravirine/Lamivudine/Tenofovir (Treatment C)	積網壓選鹹顧餘築觸鬱(壓蓋衊蓋鏇簾製憲鬱獵) = 壓壓遞糧製選範壓製繭鏇選鹹糧鑰淵繭淵繭構 (構觸鹹製窪壓鹽繭築襯, 21.7) 更多	-	2025-03-26
				Doravirine/Lamivudine/Tenofovir (Treatment A)	積網壓選鹹顧餘築觸鬱(壓蓋衊蓋鏇簾製憲鬱獵) = 醖壓廠餘齋齋憲鏇製醖鏇選鹹糧鑰淵繭淵繭構 (構觸鹹製窪壓鹽繭築襯, 41.75) 更多